Moderna COVID-19 vaccine: Difference between revisions
Content deleted Content added
→Adverse effects: Germany also restricted the vaccine |
Tag: Reverted |
||
| (One intermediate revision by the same user not shown) | |||
| Line 241: | Line 241: | ||
{{duplication span|text=In July 2020, Moderna announced in a preliminary report that its [[Operation Warp Speed]] candidate had led to production of [[neutralizing antibody|neutralizing antibodies]] in healthy adults in [[Phases of clinical research|Phase{{nbs}}I clinical testing]].<ref name=jackson /><ref>{{cite web|url=https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|title=Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus | vauthors = Li Y |publisher=[[CNBC]]|date=14 July 2020|access-date=15 July 2020|archive-date=16 November 2020|archive-url=https://web.archive.org/web/20201116154335/https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|url-status=live}}</ref> "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection."<ref name=mhdg/> The troublesome higher doses were discarded in July from future studies.<ref name="mhdg">{{cite news | vauthors = Herper M, Garde D |title=First data for Moderna Covid-19 vaccine show it spurs an immune response |url=https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ |work=[[Stat (website)|Stat]] |publisher=Boston Globe Media |date=14 July 2020 |access-date=15 July 2020 |archive-date=14 July 2020 |archive-url=https://web.archive.org/web/20200714221558/https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ |url-status=live }}</ref>|date=August 2021}} |
{{duplication span|text=In July 2020, Moderna announced in a preliminary report that its [[Operation Warp Speed]] candidate had led to production of [[neutralizing antibody|neutralizing antibodies]] in healthy adults in [[Phases of clinical research|Phase{{nbs}}I clinical testing]].<ref name=jackson /><ref>{{cite web|url=https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|title=Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus | vauthors = Li Y |publisher=[[CNBC]]|date=14 July 2020|access-date=15 July 2020|archive-date=16 November 2020|archive-url=https://web.archive.org/web/20201116154335/https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|url-status=live}}</ref> "At the 100-microgram dose, the one Moderna is advancing into larger trials, all 15 patients experienced side effects, including fatigue, chills, headache, muscle pain, and pain at the site of injection."<ref name=mhdg/> The troublesome higher doses were discarded in July from future studies.<ref name="mhdg">{{cite news | vauthors = Herper M, Garde D |title=First data for Moderna Covid-19 vaccine show it spurs an immune response |url=https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ |work=[[Stat (website)|Stat]] |publisher=Boston Globe Media |date=14 July 2020 |access-date=15 July 2020 |archive-date=14 July 2020 |archive-url=https://web.archive.org/web/20200714221558/https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/ |url-status=live }}</ref>|date=August 2021}} |
||
On 14 September 2021, a study reported a strong immune response after six months, even at low doses, suggesting that more doses could be deployed from a limited vaccine supply. Six months after low-dose vaccination, 67% of participants still had [[Memory T cell|memory]] [[Cytotoxic T cell|cytotoxic T cells]], suggesting that immune memory is stable. The study also found that [[Cross-reactivity|cross-reactive]] T cells acquired during infection with other coronaviruses that cause the common cold increased the response to the vaccine.<ref>{{Cite journal |vauthors=Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, Sette A, Crotty S, Weiskopf D |display-authors=6 |title=Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells |url=https://www.science.org/doi/10.1126/science.abj9853 |journal=Science |volume=374 |issue=6566 |doi=10.1126/science.abj9853 |pmc=PMC8542617 |pmid=34519540}}</ref> |
|||
==== Phase III ==== |
==== Phase III ==== |
||